A Landmark Point Analysis with Cytotoxic Agents for Advanced NSCLC  by Yamamoto, Nobuyuki et al.
ORIGINAL ARTICLE
A Landmark Point Analysis with Cytotoxic Agents
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and Minori Koshiji, MD, PhD†
Introduction: As a result of recent publications, we hypothesized
that period of 8 weeks after initiation of treatment is a useful
landmark point for cytotoxic agents for advanced non-small cell
lung cancer (NSCLC). To test this hypothesis, we conducted land-
mark analyses with clinical trials employing cytotoxic agents. Our
goal was to assess the proper design of clinical trials with cytotoxic
agents for NSCLC for maximizing patients’ benefit.
Methods: We conducted landmark analyses of a phase II study of
pemetrexed in locally advanced or metastatic NSCLC and a phase
III study of Four-Arm Cooperative Study for advanced NSCLC. A
total of 806 patients who received chemotherapy (pemetrexed, cisplatin
and irinotecan, paclitaxel and carboplatin, cisplatin and gemcitabine,
cisplatin and vinorelbine) were included in this assessment.
Results: Tumor-shrinkage rate at 8 weeks was significantly associ-
ated with longer survival in the study with pemetrexed (p  0.043),
whereas tumor-shrinkage rate at 4 weeks did not correlated with
survival (p  0.139). Similarly, using the Four-Arm Cooperative
Study data, the optimal landmark point was 8 weeks (p 0.002), not
4 weeks (p  0.190).
Conclusion: The landmark point for NSCLC was 8 weeks with all
cytotoxic agents in our analysis when the therapy was given as a
frontline or subsequent therapy. Our result suggests the concept of a
disease-specific landmark point, which may lead to a change of
phase II/III clinical study design to evaluate cytotoxic agents and
clinical investigators, and their sponsors may consider an early look
to assess the efficacy of cytotoxic agents for NSCLC.
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Non-small cell lung cancer (NSCLC) is the most commontype of lung cancer worldwide and many clinical studies
are currently assessing new chemotherapy combinations for
NSCLC.1–5 Currently, in most phase II/III, clinical trials for
advanced NSCLC use overall survival (OS) as a primary end
point6–10 and patients continue treatment until progressive dis-
ease (PD), unacceptable toxicity, or withdrawal of consent,11–13
resulting in the median number of cycles being delivered from
three to four. Treatment is discontinued for disease refractory to
treatment or the patient could not tolerate the toxicities of
treatment beyond three to four cycles.13 Also, it was reported
that objective responses and palliation of symptoms typically
occurred within the first two to three cycles of therapy.14
Therefore, we attempted to assess the proper design of
clinical trial targeting advanced NSCLC, including duration
of treatment and optimal response measurement.
To assess the proper length of clinical study for NSCLC,
we conducted landmark analyses of NSCLC clinical trials.
The landmark method is a valid method for evaluating sur-
vival by tumor response.15 Recently, landmark survival anal-
ysis of a large Southwest Oncology Group database revealed
that week 8 is a landmark point for first-line therapy for
advanced NSCLC with platinum-based chemotherapy.16
In this study, we also hypothesized that week 8 is a
landmark point for advanced NSCLC patients with any cy-
totoxic regimens regardless of line of therapy. To test this
hypothesis, we conducted landmark survival analyses of a
phase II study of pemetrexed as salvage in metastatic NSCLC
patients who have prior chemotherapy (the pemetrexed phase
II study),17 and Four-Arm Cooperative Study (the FACS study) a
phase III study for previously untreated advanced NSCLC.18 The
present study will potentially provide scientific evidence supporting
change of the paradigm for late phase clinical trial design.
PATIENTS AND METHODS
Original Clinical Studies
These landmark analyses were performed on two
clinical studies. One was a phase II study of pemetrexed as
salvage in metastatic NSCLC patients who had prior chemo-
therapy.17 In this phase II study, pemetrexed 500 or 1000 mg/m2
was administrated every 3 weeks. Patients had to meet the
following inclusion criteria: clinical stage III or IV NSCLC, at
least one target lesion, one or two prior chemotherapeutic
regimens, age 20 to 75 years old, Eastern Cooperative On-
cology Group performance status 0 to 2, and adequate hema-
tological, hepatic, and renal functions.
The other was a phase III cooperative group study of
four arms for advanced untreated NSCLC patients.18 In the
four arms of this phase III study, the combination chemother-
apies of cisplatin plus irinotecan, paclitaxel plus carbopla-
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tin, cisplatin plus gemcitabine, or cisplatin plus vinorel-
bine were given, respectively: cisplatin 80 mg/m2 on day 1
plus irinotecan 60 mg/m2 on days 1, 8, 15 every 4 weeks (IP);
carboplatin area under the curve 6.0 minutes mg/ml on day
1 plus paclitaxel 200 mg/m2 on day 1 every 3 weeks (TC);
cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on
days 1, 8 every 3 weeks (GP); and cisplatin 80 mg/m2 on day
1 plus vinorelbine 25 mg/m2 on days 1, 8 every 3 weeks (NP).
Patients had to meet the following criteria: clinical stage IIIB
or IV NSCLC, no prior chemotherapy, no prior surgery and/or
radiotherapy for the primary site, age 20 to 74 years old,
Eastern Cooperative Oncology Group performance status 0 or
1, and adequate hematological, hepatic, and renal functions.
In all five treatment arms of these two studies, tumor sizes
were assessed every 4 weeks by diagnostic computed tomogra-
phy scan (slice thickness10 mm) and the evaluation of tumor
response was performed using the RECIST criteria.
Original publications have already been published;17,18
however, the result reported in this article is not shown in
both previous publications.
Statistical Analysis
Statistical analyses were carried out to assess the asso-
ciation of the intermediate outcomes with OS, using the
landmark method which could evaluate responses for all
patients at some fixed time after the onset of treatment.19
Briefly, using data of the pemetrexed phase II study or the
FACS study, two separate analyses were completed at 4 and
8 weeks from the start of treatment. In each analysis, patients
are divided into two groups according to their tumor-shrinkage
rates (TSRs). “TSR0%” means tumor size “decreased” or “no
change.” All patients who were eligible for efficacy analysis
were categorized as responder (TSR0) or nonresponder (TSR
0) at the landmark point. A logrank test was used to assess the
association between disease status at the landmark times. The
data analysis was generated using SAS/STAT software, Version
8.2 of the SAS system for PC (SAS Inc., Cary, NC).
RESULTS
Patient Characteristics
The Pemetrexed Phase II Study
Table 1 summarizes the characteristics of patients in-
cluded in the pemetrexed registration study. Two hundred
twenty-six patients were enrolled into this study and received
pemetrexed 500 mg/m2 or 1000 mg/m2 every 3 weeks. At the
time of unblinding and study analysis, 10 patients had dis-
continued therapy. Therefore, 216 patients were evaluable for
efficacy: 137 male (63%) and 79 female (37%). One hundred
seventy three patients (80%) had stage IV disease and 43
patients (20%) had stage IIIB disease. A total of 72.7% patients
were diagnosed as adenocarcinomic. Prior to pemetrexed all
patients received one or two chemotherapy regimens.
The FACS Study
The characteristics of patients included in the FACS
study are shown in Table 1. A total of 602 patients were
randomly assigned into one of four regimens: cisplatin 80
mg/m2 on day 1 plus irinotecan 60 mg/m2 on days 1, 8, 15
every 4 weeks (IP); carboplatin area under the curve 6.0
minutes  mg/ml on day 1 plus paclitaxel 200 mg/m2 on day
1 every 3 weeks (TC); cisplatin 80 mg/m2 on day 1 plus
gemcitabine 1000 mg/m2 on days 1, 8 every 3 weeks (GP);
and cisplatin 80 mg/m2 on day 1 plus vinorelbine 25 mg/m2
on days 1, 8 every 3 weeks (NP). Ten patients did not receive
chemotherapy and 11 patients were subsequently found to be
ineligible. Therefore, 581 patients were assessable for effi-
cacy: 398 male (69%) and 183 female (31%). Four hundred
sixty-six patients (80%) had stage IV disease and 115 patients
(20%) had stage IIIB disease.
Best Response to Treatment and Survival
Table 2 and Figures 1A, B show best response to treatment
and OS in the pemetrexed phase II study and the FACS study.
TABLE 1. Patients Characteristics and Treatment Delivery in Phase II Study of Pemetrexed and FACS Study
Chemotherapy Pts
Gender
(Male/Female)
Age
Median (Range)
PS
(PS0/PS1/PS2)
Histology
Stage
IIIB/IVAdeno Squamous Others
Pemetrexed17 216 137/79 62 (26–74) 79/125/12 157 48 11 43/173
Cisplatin/irinotecan18 145 97/48 62 (30–74) 44/101/0 121 16 8 31/114
Carboplatin/paclitaxel18 145 99/46 63 (33–74) 44/101/0 104 31 10 28/117
Cisplatin/gemcitabine18 146 101/45 61 (34–74) 45/101/0 108 29 9 30/116
Cisplatin/vinorelbine18 145 101/44 61 (28–74) 45/100/0 109 29 7 26/119
Pts, number of patients; PS, performance status; FACS, Four-Arm Cooperative Study.
TABLE 2. Best Response to Treatment in a Phase II Study of
Pemetrexed and FACS Study
Clinical Study
Phase II Study
of Pemetrexed FACS Study
No. of patients 216 581
Response
CR 0 1 (0.2%)
PR 36 (16.7%) 183 (31.5%)
SD 74 (34.3%) 245 (42.2%)
PD 106 (49.1%) 120 (20.7%)
Not evaluated 0 32 (5.5%)
FACS, Four-Arm Cooperative Study; CR, complete response; PR, partial response;
SD, stable disease; PD, progressive disease.
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Landmark Point
As shown in Table 3 and Figure 2A, using data of the
pemetrexed phase II study, there was a survival advantage
among patients who had achieved a response (TSR 0) at 8
weeks after registration (p  0.043), whereas there was no
significant association between response and survival at 4 weeks
after registration (p  0.139). Table 3 and Figure 2B demon-
strate that 8 weeks is also a landmark point with patients
participated in the FACS study (p  0.002), whereas there was
no survival advantage among patients who achieved a response
(TSR 0) at 4 weeks after registration (p  0.190).
DISCUSSION
Duration of Treatment
In 1989, Buccheri et al.20 reported a randomized trial of
nonplatinum-based chemotherapy with stable disease (SD)
after two or three cycles of chemotherapy to continued
treatment or best supportive care. No survival benefit was
seen with continuous treatment in this subset of patients with
SD. In 2001, Smith et al.21 reported a randomized trial of
three cycles versus six cycles of platinum-based chemother-
apy in 308 patients with stage III/IV advanced NSCLC. Of
the patients randomized to three cycles, 72% completed
therapy, whereas only 31% of the patients randomized to six
cycles completed therapy.21 No advantage was seen for the
longer duration of therapy.21 In addition, more toxicity was
reported compared with patients receiving the longer duration
(six cycles) of therapy. In 2007, Park et al.22 demonstrate
improved time to progression with extended duration of
platinum-based therapy (four cycles versus six cycles), with-
out no survival benefit. In 2008, Lara et al.16 reported that
week 8 is a landmark point for first-line therapy for advanced
NSCLC with platinum-based chemotherapy. Although Lara
et al. used disease control rate (DCR), instead of using
traditional response rate, it was shown that tumor response at
week 8 was significantly associated with survival benefit for
advanced NSCLC patients treated with platinum-based che-
motherapy.
In this study, we conducted landmark analyses with the
pemetrexed phase II and the FACS studies. In line with the
previous report of Lara et al., our data demonstrate that week
8 is a landmark point for FACS study, which is four-armed
comparison study of platinum-based regimens (cisplatin plus
irinotecan, paclitaxel plus carboplatin, cisplatin plus gemcit-
abine, and cisplatin plus vinorelbine) as a frontline-combina-
tion therapy. Interestingly, tumor response at week 8 is also
correlated to survival benefit in patients treated with pem-
etrexed as a salvage agent, which supports previous studies
reporting that objective responses and palliation of symptoms
typically occurred within the first two to three cycles of
therapy.14
For landmark analysis, all available patients’ data were
used. However, tumor response was not assessed precisely
every 4 weeks and some patients did not get response assess-
ment at week 4. Thus, there are potential limitations for
determination of an accurate landmark point and we can not
FIGURE 1. Overall survival curve by Kaplan-Meier. Phase II study of Pemetrexed (A) and Four-Arm Cooperative Study (FACS) (B).
TABLE 3. Tumor Shrinkage Rate in the Phase II Pemetrexed
Study and in the FACS Study
Items
4 wk 8 wk
Decrease or
No Change Increase
Decrease or
No Change Increase
Phase II study
of Pemetrexed
No. of patients 91 56 119 76
No. of events 54 38 62 50
MST (mo) 13.0 10.5 14.5 10.4
95% CI 11.3–18.0 6.5–13.5 10.8–NA* 6.6–13.0
Log-rank test p  0.139 p  0.043
FACS Study
No. of patients 328 43 497 61
No. of events 264 37 403 55
MST (mo) 12.6 12.2 12.1 8.8
95% CI 11.4–14.3 9.1–13.4 11.0–13.5 7.2–12.0
Log-rank test p  0.190 p  0.002
* Not calculated because of censored events.
FACS, Four-Arm Cooperative Study; MST, median survival time; CI, confidence
interval.
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deny the possibility for week 4 as a landmark point. To get
more accurate landmark point, future confirmation with ad-
ditional week 4 data were required. Furthermore, to achieve
equivalent precision to previous report by Lara et al.,16 the
landmark point at week 8, actually means between week 4
and week 12.
Tumor Response Assessment
For tumor response assessment, Lara et al. used DCR
consisting of complete response (CR), partial response (PR),
and SD instead of the traditional response rate of CR PR.16
In 1999, Sekine et al.23 reported that PD rate has a better
correlation with median survival time than traditional re-
sponse rate by reviewing 42 single agent phase II studies for
advanced NSCLC (3063 patients). Both previous reports
suggested that SD might be clinically relevant. According to
RECIST criteria, PR is defined as 30% or greater decrease in
the sum of the measurable lesions and PD as a 20% or greater
increase or appearance of new lesions.24 Therefore, achieve-
ment of SD does not necessarily mean “nonresponders,” and
there are both “responders” and “nonresponders” in SD
patients. In another word, with defining the responding pa-
tients as “having any shrinkage (TSR 0%)” versus “no
shrinkage (TSR 0%)” at the landmark point, SD patients
were divided into two groups: “SD with good prognosis”
versus “SD with poor prognosis.”
To differentiate responder from nonresponder, actual
measure of tumor diameter is often used for landmark anal-
ysis assessing efficacy-related issue.25,26 We demonstrated
that TSR at week 8 was significantly associated with longer
survival in both the pemetrexed phase II study and the FACS
study. Our study not only confirmed previous reports14,16 but
also showed usefulness of TSR.
Application of Landmark Point
Together with the publication by Lara et al., week 8
may be a landmark point for advanced NSCLC patients with
any cytotoxic treatments, regardless of the type of therapy.
Our findings lend support to the idea that there might be a
disease-specific landmark point, which has broad implica-
tions for future clinical trial design.
Although our results are preliminary and need to be
validated in the prospective settings, proper length for clinical
trials for advanced NSCLC can be much shorter. Clinical
investigators and their sponsors may consider an early look to
assess the efficacy of cytotoxic drugs for NSCLC. If this
landmark point can be prospectively confirmed then TSR
and/or DCR at week 8 can be used in phase II trials to screen
new treatments for activity in advanced NSCLC instead of
traditional endpoints such as response rate or progression-free
survival.
As far as clinical trials are concerned, we can not deny
that response is a marker which selects the good prognosis
patient and nonresponder may be resistant to any treatments.
To demonstrate superior efficacy in a comparison setting,
switching experiments are required to provide evidence for a
meaningful clinical benefit with changing therapy. However,
the crossover design to evaluate anticancer drug has been
considered difficult because of relatively short lung cancer
patients’ life in oncology in general. Our findings may help to
optimize the balance between patients’ survival benefit and
scientific validity by providing statistical rationale for the
switching point in crossover studies in cancer patients. As-
sessing the effectiveness of the switched therapy, we need to
have appropriate efficacy parameters to evaluate potential of
the agent used in a salvage setting, because it was previously
reported that the agent is less effective and more toxic when
it is used as a second-line treatment for NSCLC.27–29 Our
statistical rationale can still be useful to determine the dura-
tion of salvage therapy, and tumor response can be assessed
at the landmark point from the point of change.
For clinical practice, our findings may provide a rationale
for the overall management strategy of advanced NSCLC. If
week 8 is validated for disease-specific landmark point of
NSCLC with cytotoxic agents, the duration of first-line therapy
FIGURE 2. Survival by response at week 8. Phase II study of Pemetrexed (A) and Four-Arm Cooperative Study (FACS) (B).
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and timing of maintenance or sequential therapy should also be
addressed prospectively using the landmark point.
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